Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 7, pp. 752-761
Open Access | Times Cited: 338

Showing 1-25 of 338 citing articles:

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker, Matthew H. Taylor, Carol Aghajanian, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 26, pp. 2981-2992
Open Access | Times Cited: 447
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 23, pp. 2159-2170
Open Access | Times Cited: 378
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Nadeem R. Abu‐Rustum, Catheryn M. Yashar, Rebecca C. Arend, et al.
Journal of the National Comprehensive Cancer Network (2023) Vol. 21, Iss. 2, pp. 181-209
Closed Access | Times Cited: 337
Hot and cold tumors: Immunological features and the therapeutic strategies
Lianjie Wang, Hui Geng, Yujie Liu, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 95
Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy
Lei Cao, Huixiang Tian, Man Fang, et al.
Biomaterials (2022) Vol. 290, pp. 121856-121856
Open Access | Times Cited: 92
Immune Checkpoint Inhibitor Therapy in Oncology
Sean Tan, Daphne Day, Stephen J. Nicholls, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 579-597
Open Access | Times Cited: 87
Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors
Szonja Anna Kovács, János Tibor Fekete, Balázs Győrffy
Acta Pharmacologica Sinica (2023) Vol. 44, Iss. 9, pp. 1879-1889
Open Access | Times Cited: 77
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Vicky Makker, Nicoletta Colombo, Antonio Casado, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 16, pp. 2904-2910
Open Access | Times Cited: 64
Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives
Ilaria Cuccu, Ottavia D’Oria, Ludovica Sgamba, et al.
Healthcare (2023) Vol. 11, Iss. 4, pp. 571-571
Open Access | Times Cited: 53
Molecular tumour boards — current and future considerations for precision oncology
Apostolia M. Tsimberidou, Michael Kahle, Henry Hiep Vo, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 843-863
Closed Access | Times Cited: 51
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 614-614
Open Access | Times Cited: 45
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
Giorgio Bogani, Bradley J. Monk, Matthew A. Powell, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 414-428
Closed Access | Times Cited: 35
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1135-1146
Closed Access | Times Cited: 26
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
M.A. Powell, Line Bjørge, Lyndsay Willmott, et al.
Annals of Oncology (2024) Vol. 35, Iss. 8, pp. 728-738
Open Access | Times Cited: 22
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
Toon Van Gorp, David Cibula, Weiguo Lv, et al.
Annals of Oncology (2024) Vol. 35, Iss. 11, pp. 968-980
Closed Access | Times Cited: 20
Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment
Holly Baker‐Rand, Sarah Kitson
Cancers (2024) Vol. 16, Iss. 5, pp. 1028-1028
Open Access | Times Cited: 16
The Role of Immune Checkpoint Inhibitors in Cancer Therapy
Ahmed Basudan
Clinics and Practice (2022) Vol. 13, Iss. 1, pp. 22-40
Open Access | Times Cited: 61
Endometrial carcinosarcoma
Giorgio Bogani, Isabelle Ray‐Coquard, Nicole Concin, et al.
International Journal of Gynecological Cancer (2022) Vol. 33, Iss. 2, pp. 147-174
Open Access | Times Cited: 51
Current Approaches to the Management of Patients with Endometrial Cancer
Emmanouil Kalampokas, Georgios Giannis, Theodoros Kalampokas, et al.
Cancers (2022) Vol. 14, Iss. 18, pp. 4500-4500
Open Access | Times Cited: 43
Endometrial cancer: Part I. Basic concept
Peng‐Hui Wang, Szu‐Ting Yang, Chia-Hao Liu, et al.
Taiwanese Journal of Obstetrics and Gynecology (2022) Vol. 61, Iss. 6, pp. 951-959
Closed Access | Times Cited: 42
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Xuan Zhao, Yulin Bao, Bi Meng, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 40
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4564-4574
Open Access | Times Cited: 31
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
Vicky Makker, Carol Aghajanian, Allen Lee Cohn, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 5, pp. 974-979
Open Access | Times Cited: 27
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 3, pp. 286-296
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top